Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly to buy rights to Centrexion’s non-opoid pain asset CNTX-0290
CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.
CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.
The settlement resolves the state’s claims against Teva. The settlement does not establish any wrongdoing on the part of the company; Teva has not contributed to the abuse
Lyrica could not show a statistically significant reduction in seizure frequency in comparison to placebo in the late-stage trial held in 219 patients aged between five and 65
KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were
The licensing rights of Raxone to Chiesi Group will be applicable in all countries with the exception of the US and Canada and in LHON and all other
Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug
This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction.
QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate, which was delivered with the dose-confirming BreezhalerIGB gas pipeline inhalation device during the mid-stage trials. The
Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The
The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting